30 recruiting, 19 unknown, 5 completed, 3 not yet recruiting. 56 Phase 1, 16 Phase 2, 2 Early Phase 1.
Follow Chongqing Precision Biotech Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma Invivo CAR-T - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 15 | 2026-07-31 | 2026-07-20 |
| Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Puzolcabtagene Autoleucel Injection - Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) | Not yet recruiting | Chongqing Precision Biotech Co., Ltd | 200 | 2026-06-01 | 2026-06-10 | |
| PIC1 Injection Therapy for Relapsed/Refractory B-NHL PIC1 Injection - Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 18 | 2026-03-01 | 2026-03-06 |
| Study of CD19 CAR-T Therapy for Refractory SLE PTOC1 - Systemic Lupus Erythematosus | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 18 | 2026-02-01 | 2026-02-11 |
| Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE BCMA/CD70 CAR-T cells - Systemic Lupus Erythematosus | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 18 | 2026-01-26 | 2026-02-03 |
| Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE CD19 CAR-T cells - Systemic Lupus Erythematosus | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 18 | 2026-01-01 | 2026-01-12 |
| CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases CEA-targeted CAR-T cells - Peritoneal Metastases From Colorectal Cancer | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 12 | 2025-11-03 | 2025-11-25 |
| A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) - NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 48 | 2025-10-13 | 2025-11-26 |
| CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors CEA-targeted CAR-T cells - Lung Cancer, Gastric Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 108 | 2025-09-12 | 2025-10-02 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors CD70-targeted CAR-T cells - Renal Cell Carcinoma (RCC), Lung Cancer | Phase 1 | Suspended | Chongqing Precision Biotech Co., Ltd | 90 | 2025-09-12 | 2026-09-11 |
| Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases BCMA/CD70-targetd CAR-T - Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 11 | 2025-09-01 | 2025-09-19 |
| In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies Invivo CAR-T - B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 24 | 2025-07-01 | 2025-11-20 |
| Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE MC-1-50 - Systemic Lupus Erythematosus (SLE), Refractory | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 12 | 2025-06-12 | 2025-12-22 |
| Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer Targeted CEA CAR-T - Advanced Lung Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 60 | 2025-05-08 | 2025-05-28 |
| Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer Targeted CEA CAR-T - Advanced Lung Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 60 | 2025-04-28 | 2025-06-04 |
| Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE anti-BCMA/CD70-CAR-T cells - CAR T Cell Therapy, Systemic Lupus Erythematosus | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 18 | 2025-04-25 | 2025-04-25 |
| Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies Anti-CD5 CAR NK cells - T-ALL/Lymphoma | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 15 | 2025-03-27 | 2025-04-03 |
| Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma Targeted CEA CAR-T - Advanced Lung Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 60 | 2025-03-24 | 2025-04-03 |
| A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer Targeted CEA CAR-T - Advanced Lung Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 48 | 2024-12-12 | 2025-01-10 |
Showing 20 of 60. Sign in to see all of them.
Stomach Neoplasms (10) · Pancreatic Neoplasms (9) · Neoplasm Metastasis (8) · Esophageal Neoplasms (7) · Lupus Erythematosus, Systemic (7) · Breast Neoplasms (6) · Carcinoma, Renal Cell (6) · Lung Neoplasms (6) · Lymphoma, B-Cell (6) · Multiple Myeloma (6) · Ovarian Neoplasms (6) · Uterine Cervical Neoplasms (6) · Colonic Neoplasms (5) · Colorectal Neoplasms (5) · Leukemia (5)
Antigens, CD19 (4) · Immunotherapy, Adoptive (1)
China (59)
Cheng Qian, PhD (11) · Sanbin Wang, MD (7) · Jianfeng Bi, M.D (3) · Weijia Fang, M.D (3) · Ying Xiang, MD (3) · Donglai Lv, MD (2) · Fei Li, M.D (2) · Jia Wei, M.D (2) · Jianfeng Zhou, M.D. Ph.D (2) · Jianhua Mao, MD (2) · Fuming Qiu, PhD (1) · Guantai Ni, M.D (1) · Jingwang Bi, M.D (1) · Junqiang Fan, PhD (1) · Lifeng Sun (1)
PMID 28925994, PMID 30592986, PMID 30842314, PMID 31974366, PMID 32472023, PMID 34347960, PMID 36109639, PMID 36775248, PMID 39734708, PMID 41039358, PMID 41760800